Reaction
Oncologic Complication reporting signals
As of the last recalculation, Oncologic Complication appears in 961 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 21.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 30 | 21.9 | 21.9 |
| Cetuximab | 29 | 20.6 | 20.7 |
| Nilotinib | 26 | 19.6 | 19.6 |
| Everolimus | 44 | 19.6 | 19.6 |
| Fam-Trastuzumab Deruxtecan-Nxki | 7 | 15.1 | 15.2 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 5 | 13.3 | 13.3 |
| Enzalutamide | 31 | 11.8 | 11.8 |
| Imatinib Mesylate | 12 | 9.4 | 9.4 |
| Osimertinib | 11 | 7.5 | 7.5 |
| Alpelisib | 3 | 7.5 | 7.5 |
| Lapatinib | 5 | 7.0 | 7.0 |
| Leuprolide Acetate | 22 | 6.3 | 6.3 |
| Olaparib | 6 | 6.2 | 6.2 |
| Relugolix | 5 | 4.6 | 4.6 |